Jorge E. Cortes, MD

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.

The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.

The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.

Experts on chronic myeloid leukemia delve into the important role of informed shared decision-making in the optimal treatment of patients with CML.

Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.

Jorge Cortes, MD, provides clinical insights on the utilization of TKIs in CML and outlines associated adverse events.

The Oncology Brothers and Jorge Cortes, MD, discuss treatment practices for patients with accelerated phase chronic myeloid leukemia.

An expert on chronic myeloid leukemia provides clinical insights on treatment practices following progression.

A hematologist-oncologist and the Oncology Brothers outline treatment paradigms for chronic phase CML and discuss patient monitoring practices.

Jorge Cortes, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss patient workup and risk stratification practices in chronic myeloid leukemia (CML).

Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.

A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.

Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies that optimize communication when considering treatment options.

Experts on chronic myeloid leukemia discuss how caregivers can collaborate with the health care team and support newly diagnosed patients.

Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.

Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.

Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.

Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.

Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.

Experts review future implications such as using ponatinib in earlier lines of therapy and in patients with Ph-positive ALL.

Jorge E. Cortes, MD and Hagop Kantarjian, MD debate optimal dosing and discuss how they use ponatinib in patients with CML.

Hagop Kantarjian, MD responds to a review of dosing options in patients with CML treated with ponatinib.

Dr. Cortes reviews ponatinib dosing strategies based on patient profiles and mutational status.

Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.

Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.

“I’ve done a lot of work [not only with] clinical trials, but also understanding the disease, the prognostic factors, and the management of adverse effects.”

This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis.